[Study on clinicopathological correlations between metabolic syndrome and colorectal carcinoma].
OBJECTIVE
To explore the clinicopathological relationship between metabolic syndrome (MS) and colorectal cancer.


METHODS
The clinical data of 507 cases of colorectal cancer (colorectal cancer group) and 277 cases of nontumorous diseases (control group) treated from January 2002 to March 2007 were collected to set up the database. The patients with colorectal carcinoma were divided into two groups according to the presence of MS: MS group and non-MS group. Some clinicopathological factors were analyzed and compared between the two groups, such as age, gender, blood pressure, tumor family history, hypertension and diabetes mellitus history, body mass index (BMI), glucose (GLU), triglyceride (TG), cholesterol (CHO), high density lipoprotein (HDL), lactate dehydrogenase (LDH), uric acid (UA), carcinoembryonic antigen (CEA) , CA19-9, the tumor position, pathological stage, and liver metastasis.


RESULTS
The morbidity rate of metabolic syndrome in the colorectal cancer group was significantly higher than that in control group. The rate of liver metastasis and tumor recurrence in the MS group was significantly higher than that in the non-MS group.


CONCLUSIONS
To understand the relationship between MS and colorectal cancer is important for reducing the incidence of MS and colorectal cancer and the recurrence of the tumor and live metastasis.
Shen
Zhan-Long
ZL
Department of Gastroenterological Surgery, Peking University People's Hospital, Beijing 100044, China. shenlong1977@163.com
Wang
Shan
S
Ye
Ying-Jiang
YJ
Yin
Mu-Jun
MJ
Yang
Xiao-Dong
XD
Jiang
Ke-Wei
KW
Liu
Yan
Y
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015179:Colorectal Neoplasms / Q000150:complications / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications*; D008875:Middle Aged; D011379:Prognosis